Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
26 authors.
Hiroya OkamotoDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0001-0795-6895
Takayoshi TobaDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0002-0205-928X
Yoichiro SugizakiDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0005-2092-4360
Hiroyuki KawamoriDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0001-6810-447X
Takashi HiromasaDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0007-6111-1846
Daichi FujimotoDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.
Yu IzawaDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0002-2688-3468
Yuto OsumiDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0003-0177-0173
Tetsuya YamamotoDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0003-4444-0289
Seigo IwaneDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0004-1895-7828
Shota NaniwaDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0004-9062-8869
Chiaki YoshidaDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.
Yuki SakamotoDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0002-1592-3647
Koshi MatsuhamaDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0007-2973-2976
Yuta FukuishiDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0003-1809-5781
Hiroshi TsunamotoDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.
Kotaro HiguchiDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0009-1965-1130
Nobuhiro WatanabeDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0008-8170-8217
Ken TakataDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0008-0920-6706
Keisuke IidaDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0009-0770-731X
Tatsuya KitagawaDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0000-4174-7141
Mayuka MasudaDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0003-4346-8095
Shotaro YoshidaDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.
Hiromi HashimuraDepartment of Radiology Kobe University Graduate School of Medicine Kobe Japan.ORCID 0009-0003-7520-7225
Takamichi MurakamiDepartment of Radiology Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0001-7782-548X
Hiromasa OtakeDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0001-9953-0551
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundPerivascular adipose tissue (PVAT) attenuation interacts with local and systemic vascular inflammation and consequently contributes to unfavorable clinical outcomes in patients with various cardiovascular diseases.
methodsWe retrospectively analyzed consecutive patients with severe aortic stenosis to investigate the association between PVAT attenuation measured before transcatheter aortic valve replacement (TAVR) and subsequent clinical outcomes. PVAT attenuation was measured using computed tomography angiography images around the aortic valve. The primary outcome was defined as major adverse cardiovascular events (MACE), a composite of all-cause death, stroke, and heart failure rehospitalization.
resultsMACE was observed in 23.6% of 233 patients during a median follow-up of 2.2 years. The MACE group had significantly higher PVAT attenuation than the non-MACE group (-74.0±9.8 Hounsfield unit [HU] versus -78.9±9.2 HU,
conclusionsElevated PVAT attenuation around the aortic valve was associated with MACE in patients undergoing TAVR. Measuring PVAT attenuation before TAVR can help identify patients at higher risk of developing heart failure or cardiovascular death after TAVR, thereby aiding in treatment strategy decisions. REGISTRATION: URL: https://www.umin.ac.jp/ctr/; Unique Identifier: UMIN000057107.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Impact of Perivascular Adipose Tissue Attenuation Around the Aortic Valve on Clinical Outcomes After Transcatheter Aortic Valve Replacement. · full record | OpenQuestion